USDA Approves US Biologic’s Oral Lyme Disease Vaccine for Wildlife

TCORS Capitol Group, LLC (TCG) congratulates client US Biologic on their recent groundbreaking achievement in disease prevention: the USDA has approved its oral vaccine for Lyme Disease in wildlife. 

“US Biologic, a leading global entity in the development, commercialization, and distribution of orally delivered vaccines, announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.

The only known vector is the blacklegged tick, which is infected primarily by feeding on small wildlife mammals, particularly white-footed mice. The vaccine, called “Borrelia Burgdorferi Bacterin,” is spray-coated onto pellets that the mice consume.

Field trials demonstrating real-world impact have been conducted and co-published by the Cary Institute of Ecosystem Studies, the CDC, the Connecticut Agricultural Experiment Station (CAES), the University of Pennsylvania, the University of Tennessee Health Science Center, Yale University, and others.”

Read the full article here.